Needham & Company Upgrades ResMed (RMD) to Buy
Tweet
Share
E-mailGet Alerts RMD Hot Sheet
Price: $222.00 +0.05%
Rating Summary:
12 Buy, 12 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 19
Rating Summary:
12 Buy, 12 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 19
Join SI Premium – FREE
Needham & Company analyst Mike Matson upgraded ResMed (NYSE: RMD) from Hold to Buy with a price target of $180.00.
For an analyst ratings summary and ratings history on ResMed click here. For more ratings news on ResMed click here.
Shares of ResMed closed at $153.89 yesterday.
You May Also Be Interested In
- HSBC Upgrades Synopsys (SNPS) to Buy, 'Transforming into an AI beneficiary'
- UBS Upgrades Stem Inc. (STEM) to Buy
- HSBC Upgrades BP Plc. (BP:LN) (BP) to Buy
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
